Takeda Pharmaceutical Co.’s global footprint mirrors how most drug companies operate today. Multinational pharmaceutical companies tend to build one manufacturing plant to produce one treatment, which is then shipped to different markets across the globe.
But with the ongoing uncertainty of tariffs, enacted by President Donald Trump’s administration in China and threatened in other markets including Canada and Mexico, global companies like Tokyo-based Takeda may need to rethink their approach to ensure their supply chains remain resilient.
